OncoSil Medical Ltd. announced that Mr. Brian Leedman has been appointed to the Board as a Non-Executive Director. Mr. Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr. Leedman is the founder of ResApp Diagnostics Pty Ltd. which was acquired by Narhex Life Sciences Limited to form ResApp Health Limited where Mr. Leedman is the Executive Director of Corporate Affairs.

ResApp Health is currently under a Scheme of Arrangement to be acquired by Pfizer (Aust) Limited. Mr. Leedman is an experienced public company director having formerly been the Chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and was a Director of Alcidion Corporation Limited. Prior to ResApp, Mr. Leedman co-founded OncoSil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited).

Mr. Leedman previously served for ten years as Vice President, Investor Relations for pSivida Corp. Limited, which was listed on the ASX, Frankfurt and NASDAQ. He was formerly the WA Chairman of AusBiotech, the association of biotechnology companies in Australia.

Mr. Leedman holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia.